Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Serum levels of S100B, S1… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury.

Artikel i vetenskaplig tidskrift
Författare Karin Nylén
Martin Öst
Ludvig Z Csajbok
Inger Nilsson
C Hall
Kaj Blennow
Bengt Nellgård
Lars Rosengren
Publicerad i Acta neurochirurgica
Volym 150
Nummer/häfte 3
Sidor 221-7; discussion 227
ISSN 0942-0940
Publiceringsår 2008
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering
Institutionen för kliniska vetenskaper, Avdelningen för anestesiologi och intensivvård
Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi
Institutionen för kliniska vetenskaper
Sidor 221-7; discussion 227
Språk en
Länkar dx.doi.org/10.1007/s00701-007-1489-...
Ämnesord Adolescent, Adult, Aged, Aged, 80 and over, Biological Markers, analysis, blood, Blood-Brain Barrier, metabolism, physiopathology, Brain, physiopathology, surgery, Brain Injuries, blood, diagnosis, surgery, Child, Dimerization, Female, Glasgow Outcome Scale, Humans, Male, Middle Aged, Nerve Growth Factors, analysis, blood, Predictive Value of Tests, Protein Isoforms, analysis, blood, Protein Subunits, analysis, blood, S100 Proteins, analysis, blood, Survival Rate, Trauma Severity Indices, Treatment Outcome
Ämneskategorier Medicin och Hälsovetenskap, Neurokirurgi

Sammanfattning

OBJECTIVES: S100B is an established marker of brain damage. Used in the context as a biochemical marker, S100B denotes a measurement of all S100 proteins, including at least one S100B monomer, i.e. the sum of the two dimers S100A1B and S100BB. Almost all published studies are based on this "sum concentration". However, the brain specificity of S100B has been questioned and increased serum levels have also been reported after trauma without head injury. Since the S100B monomer dominates in the brain, we hypothesised that the S100BB dimer should be better related to outcome after severe traumatic brain injury than S100A1B or the "sum concentration". METHODS: Daily serum samples were collected from 59 patients with severe traumatic brain injury. Three different ELISA methods were used for measurements of S100B, S100A1B and S100BB respectively. Outcome was assessed after one year and categorised according to the Glasgow Outcome Scale. RESULTS: Serum levels of S100B, S100A1B and S100BB followed the same temporal course, with early maximum and rapidly decreasing values over the first days after the trauma. Maximum serum concentrations of each of the parameters were increased in the patient group with an unfavourable outcome compared with those with a favourable outcome (p = 0.01, 0.006 and 0.004, respectively). CONCLUSION: Both S100A1B and S100BB were related to outcome after severe traumatic brain injury. Even though this study is small, it seems unlikely that separate analyses of the dimers are of any advantage compared with measuring S100B alone.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?